ECSP088242A - Combinaciones que comprenden dmxaa para el tratamiento de cancer - Google Patents

Combinaciones que comprenden dmxaa para el tratamiento de cancer

Info

Publication number
ECSP088242A
ECSP088242A EC2008008242A ECSP088242A ECSP088242A EC SP088242 A ECSP088242 A EC SP088242A EC 2008008242 A EC2008008242 A EC 2008008242A EC SP088242 A ECSP088242 A EC SP088242A EC SP088242 A ECSP088242 A EC SP088242A
Authority
EC
Ecuador
Prior art keywords
combinations
dmxaa
cancer treatment
understanding
combinations understanding
Prior art date
Application number
EC2008008242A
Other languages
English (en)
Inventor
Colin Green
Lloyd Kelland
Gail Rowlinson-Busza
Original Assignee
Antisoma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antisoma Plc filed Critical Antisoma Plc
Publication of ECSP088242A publication Critical patent/ECSP088242A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se relaciona con combinaciones de la clase de los ácidos xantenona acético tales como el ácido 5,6-dimetilxantenona-4-acético (DMXAA) e inhibidores de la vía de señalización EGFR. De manera más particular, la invención se relaciona con el uso de dichas combinaciones en el tratamiento de cáncer y composiciones farmacéuticas que contienen dichas combinaciones.
EC2008008242A 2005-08-26 2008-03-05 Combinaciones que comprenden dmxaa para el tratamiento de cancer ECSP088242A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0517387.7A GB0517387D0 (en) 2005-08-26 2005-08-26 Combinations for the treatment of cancer

Publications (1)

Publication Number Publication Date
ECSP088242A true ECSP088242A (es) 2008-08-29

Family

ID=35198384

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008242A ECSP088242A (es) 2005-08-26 2008-03-05 Combinaciones que comprenden dmxaa para el tratamiento de cancer

Country Status (16)

Country Link
US (1) US20100104565A1 (es)
EP (1) EP1931331A1 (es)
JP (1) JP2009506020A (es)
KR (1) KR20080048488A (es)
CN (1) CN101296695A (es)
AU (1) AU2006283376A1 (es)
BR (1) BRPI0614964A2 (es)
CA (1) CA2620447A1 (es)
EC (1) ECSP088242A (es)
GB (1) GB0517387D0 (es)
IL (1) IL189377A0 (es)
MA (1) MA29784B1 (es)
NO (1) NO20080650L (es)
RU (1) RU2404765C2 (es)
TN (1) TNSN08057A1 (es)
WO (1) WO2007023307A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001282717A1 (en) 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
DK2076289T3 (da) 2007-04-13 2015-02-09 Dana Farber Cancer Inst Inc Fremgangsmåder til behandling af cancerresistens over for ErbB-lægemider
US8287346B2 (en) * 2008-11-03 2012-10-16 Cfph, Llc Late game series information change
US20160287623A1 (en) * 2013-11-19 2016-10-06 The University Of Chicago Use of sting agonist as cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations

Also Published As

Publication number Publication date
MA29784B1 (fr) 2008-09-01
NO20080650L (no) 2008-05-13
KR20080048488A (ko) 2008-06-02
CN101296695A (zh) 2008-10-29
TNSN08057A1 (en) 2009-07-14
US20100104565A1 (en) 2010-04-29
WO2007023307A1 (en) 2007-03-01
RU2404765C2 (ru) 2010-11-27
CA2620447A1 (en) 2007-03-01
EP1931331A1 (en) 2008-06-18
RU2008111493A (ru) 2009-10-10
AU2006283376A1 (en) 2007-03-01
IL189377A0 (en) 2008-06-05
GB0517387D0 (en) 2005-10-05
BRPI0614964A2 (pt) 2016-09-13
JP2009506020A (ja) 2009-02-12

Similar Documents

Publication Publication Date Title
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
GT200500237A (es) Derivados de pirimidina
CR20110216A (es) Derivados de ácido 1-amino-2-ciclobutiletilborónico
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
CR20180339A (es) INHIBIDORES DE PIRAZOLIL QUINAZOLINA CINASA (Divisional 2012-0576)
ECSP088242A (es) Combinaciones que comprenden dmxaa para el tratamiento de cancer
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
ECSP088800A (es) Formulaciones de inhibidores de DPP IV
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
CR20110579A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
CR10567A (es) Peptidomimeticos de smac utiles como inhibidores de proteinas de apoptosis (iap)
BR112015005862A2 (pt) derivados de hidropirrolpirrol para uso como inibidores de ácido graxo sintase
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
GT200900027A (es) Compuestos organicos
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-
GT200600117A (es) Nuevos compuestos farmaceuticos
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2008002946A1 (es) Compuestos derivados de quinazolindionas sustituidas, inhibidores pde7 y pde8; composicion farmaceutica que los comprende; procedimiento de preparacion de estos; y usos en el tratamiento y/o prevencion de enfermedades inflamatorias, inmuno inflamatorias, gi, oseas, cancer, entre otras.
UY32704A (es) Compuestos de 2,3-dihidro-1h-indeno
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.